These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 15462281)

  • 21. Safety and immunogenicity of an inactivated hepatitis A vaccine among HIV-infected subjects.
    Wallace MR; Brandt CJ; Earhart KC; Kuter BJ; Grosso AD; Lakkis H; Tasker SA
    Clin Infect Dis; 2004 Oct; 39(8):1207-13. PubMed ID: 15486846
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients.
    Gringeri A; Santagostino E; Muça-Perja M; Mannucci PM; Zagury JF; Bizzini B; Lachgar A; Carcagno M; Rappaport J; Criscuolo M; Blattner W; Burny A; Gallo RC; Zagury D
    J Hum Virol; 1998; 1(4):293-8. PubMed ID: 10195254
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunologic response to antiretroviral therapy in hepatitis C virus-coinfected adults in a population-based HIV/AIDS treatment program.
    Braitstein P; Zala C; Yip B; Brinkhof MW; Moore D; Hogg RS; Montaner JS
    J Infect Dis; 2006 Jan; 193(2):259-68. PubMed ID: 16362890
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patterns of skin manifestations and their relationships with CD4 counts among HIV/AIDS patients in Cameroon.
    Josephine M; Issac E; George A; Ngole M; Albert SE
    Int J Dermatol; 2006 Mar; 45(3):280-4. PubMed ID: 16533229
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
    Moore RD; Keruly JC
    Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of supplemental beta-carotene on immunologic indices in patients with AIDS: a pilot study.
    Fryburg DA; Mark RJ; Griffith BP; Askenase PW; Patterson TF
    Yale J Biol Med; 1995; 68(1-2):19-23. PubMed ID: 8748463
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
    Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW
    J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals.
    Lévy Y; Durier C; Lascaux AS; Meiffrédy V; Gahéry-Ségard H; Goujard C; Rouzioux C; Resch M; Guillet JG; Kazatchkine M; Delfraissy JF; Aboulker JP;
    AIDS; 2006 Feb; 20(3):405-13. PubMed ID: 16439874
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
    Li H; Zheng YH; Shen Z; Liu M; Liu C; He Y; Chen J; Ou QY; Huang ZL
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(42):2973-6. PubMed ID: 18261327
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
    Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG
    HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A multicenter evaluation of the PanLeucogating method and the use of generic monoclonal antibody reagents for CD4 enumeration in HIV-infected patients in Thailand.
    Pattanapanyasat K; Shain H; Noulsri E; Lerdwana S; Thepthai C; Prasertsilpa V; Likanonsakul S; Yothipitak P; Nookhai S; Eksaengsri A
    Cytometry B Clin Cytom; 2005 May; 65(1):29-36. PubMed ID: 15800883
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
    Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fractionated neem leaf extract is safe and increases CD4+ cell levels in HIV/AIDS patients.
    Mbah AU; Udeinya IJ; Shu EN; Chijioke CP; Nubila T; Udeinya F; Muobuike A; Mmuobieri A; Obioma MS
    Am J Ther; 2007; 14(4):369-74. PubMed ID: 17667213
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.
    Holkmann Olsen C; Mocroft A; Kirk O; Vella S; Blaxhult A; Clumeck N; Fisher M; Katlama C; Phillips AN; Lundgren JD;
    HIV Med; 2007 Mar; 8(2):96-104. PubMed ID: 17352766
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictive factors of treatment interruption duration in a cohort of HIV-1 infected patients with CD4 count greater than 350 cells per mm3.
    Fillaux J; Delpierre C; Alvarez M; Jaafar A; Marchou B; Massip P; Cuzin L
    Med Mal Infect; 2006 Jun; 36(6):335-9. PubMed ID: 16631330
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Normalized CD8+ but not CD4+ lymphocyte IL-2 expression is associated with early treatment with highly active antiretroviral therapy.
    Akerele T; Galatowicz G; Bunce C; Calder V; Lynn WA; Lightman S
    Clin Immunol; 2006 Nov; 121(2):191-7. PubMed ID: 16987710
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Syphilis and human immunodeficiency virus (HIV)-1 coinfection: influence on CD4 T-cell count, HIV-1 viral load, and treatment response.
    Kofoed K; Gerstoft J; Mathiesen LR; Benfield T
    Sex Transm Dis; 2006 Mar; 33(3):143-8. PubMed ID: 16505739
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.
    Sherman KE; Shire NJ; Cernohous P; Rouster SD; Omachi JH; Brun S; Da Silva B
    Clin Infect Dis; 2005 Oct; 41(8):1186-95. PubMed ID: 16163639
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir.
    Ananworanich J; Gayet-Ageron A; Ruxrungtham K; Chetchotisakd P; Prasithsirikul W; Kiertiburanakul S; Munsakul W; Raksakulkarn P; Tansuphasawadikul S; LeBraz M; Jupimai T; Ubolyam S; Schutz M; Hirschel B;
    Antivir Ther; 2008; 13(3):375-80. PubMed ID: 18572750
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors of immunity after hepatitis A vaccination in HIV-infected persons.
    Overton ET; Nurutdinova D; Sungkanuparph S; Seyfried W; Groger RK; Powderly WG
    J Viral Hepat; 2007 Mar; 14(3):189-93. PubMed ID: 17305885
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.